Three years follow-up of hyperopic laser in situ keratomileusis using a 500hz excimer laser system

Session Details

Session Title: Presented Poster Session: Femtolaser Refractive Applications

Session Date/Time: Saturday 05/09/2015 | 09:30-11:00

Paper Time: 09:30

Venue: Poster Village: Pod 2

First Author: : P.Sanz-Diez SPAIN

Co Author(s): :    A. Plaza-Puche   P. Yebana   S. Arba-Mosquera   J. Alio     

Abstract Details

Purpose:

To evaluate the visual, refractive, corneal aberrometric outcomes and regression of the achieved correction of hyperopia in the long-term with the sixth generation excimer laser.

Setting:

Vissum corporation and Miguel Hernández University, Alicante, Spain

Methods:

This retrospective consecutive observational case series study comprised 86 eyes of 44 patients who underwent Laser in situ keratomileusis (LASIK) to correct hyperopia with a postoperative follow-up of 3 years. LASIK procedures were performed using the 6th-generation Amaris excimer laser. Visual acuity, manifest refraction and corneal topography and aberrometry were evaluated in the follow-up.

Results:

76% of eyes had an uncorrected visual acuity of 20/20 or better. 70% of eyes had a spherical equivalent (SE) within ±0.50D. There was regression of 0.47D between the 3-36 months postoperatively. Statistical significant differences were found in the SE between 3-36 months (p<0.01), but no statistical differences were observed between 12-36 months (p=0.08). A flattening of 0.16D was observed between 3-36 months after surgery in the mean simulated keratometry. After surgery, a significant increase of root-mean-square (RMS) spherical-like, coma-like and higher-order aberrations (p<0.01) were observed. 29% of eyes required retreatment.

Conclusions:

Treatment of hyperopia using sixth-generation Amaris excimer laser provides very good results in terms of stability, efficacy, safety, predictability, and visual outcomes after 3 years. The refractive stability shows a significant regression in the first 12 months after surgery with more stable results from 12 months postoperatively.

Financial Interest:

NONE